HTG Molecular Diagnostics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.07 (-1.19 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume38,649 shs
Average Volume56,082 shs
Market Capitalization$43.05 million
P/E RatioN/A
Dividend YieldN/A

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

HTG Molecular Diagnostics logo

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.92 out of 5 stars

Medical Sector

645th out of 1,349 stocks

Analytical Instruments Industry

15th out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

Is HTG Molecular Diagnostics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than HTG Molecular Diagnostics?

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 171,800 shares, a drop of 35.4% from the August 15th total of 265,800 shares. Based on an average daily trading volume, of 85,400 shares, the short-interest ratio is currently 2.0 days.
View HTG Molecular Diagnostics' Short Interest

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for HTG Molecular Diagnostics

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its earnings results on Thursday, May, 13th. The medical research company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.95) by $0.15. The medical research company earned $1.44 million during the quarter, compared to analyst estimates of $1.40 million. HTG Molecular Diagnostics had a negative trailing twelve-month return on equity of 112.47% and a negative net margin of 218.26%.
View HTG Molecular Diagnostics' earnings history

What price target have analysts set for HTGM?

2 brokers have issued 1 year price targets for HTG Molecular Diagnostics' shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 63.5% from the stock's current price.
View analysts' price targets for HTG Molecular Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • John L. Lubniewski, President, Chief Executive Officer & Director
  • Shaun D. McMeans, CFO, Secretary, Treasurer & SVP-Administration
  • Byron T. Lawson, Chief Commercial Officer & Senior Vice President
  • Laura L. Godlewski, Chief Accounting Officer & Vice President-Finance
  • Sam M. Rua, Senior VP-Regulatory Affairs & Quality Systems

What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO?

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of HTG Molecular Diagnostics' key competitors?

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (8.42%), Cowen Prime Advisors LLC (7.85%), Samjo Capital LLC (7.35%), Vanguard Group Inc. (3.35%), Blue Water Life Science Advisors LLC (1.99%) and Worth Venture Partners LLC (1.97%).
View institutional ownership trends for HTG Molecular Diagnostics

Which institutional investors are selling HTG Molecular Diagnostics stock?

HTGM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, and Blue Water Life Science Advisors LLC.
View insider buying and selling activity for HTG Molecular Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying HTG Molecular Diagnostics stock?

HTGM stock was acquired by a variety of institutional investors in the last quarter, including Cowen Prime Advisors LLC, AIGH Capital Management LLC, Vanguard Group Inc., Samjo Capital LLC, Worth Venture Partners LLC, Morgan Stanley, Morgan Stanley, and PDT Partners LLC.
View insider buying and selling activity for HTG Molecular Diagnostics
or or view top insider-buying stocks.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $5.81.

How much money does HTG Molecular Diagnostics make?

HTG Molecular Diagnostics has a market capitalization of $43.05 million and generates $8.55 million in revenue each year. The medical research company earns $-20,870,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis.

How many employees does HTG Molecular Diagnostics have?

HTG Molecular Diagnostics employs 84 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is

Where are HTG Molecular Diagnostics' headquarters?

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at (520) 547-2827.

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.